Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eyepoint Pharma (EYPT)
:EYPT
RESEARCH TOOLSreports
Holding EYPT?
Track your performance easily
EYPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.90 - $30.99
Previous CloseN/A
Volume354.62K
Average Volume (3M)896.21K
Market Cap
$496.18M
Enterprise Value$204.47M
Total Cash (Recent Filing)$28.99M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.51
Next Earnings
Feb 27, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding68,251,030
10 Day Avg. Volume837,253
30 Day Avg. Volume896,208
Standard Deviation0.45
R-Squared0.03
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.85
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue4.36
Enterprise Value/Gross Profit4.94
Enterprise Value/Ebitda-2.03
Forecast
1Y Price Target
$29.43Price Target Upside293.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EyePoint Pharmaceuticals News
PremiumCompany Announcements
EyePoint Pharmaceuticals Strengthens Board with New Appointment
Bulls Say, Bears Say
Bulls Say
Financial Strength And Development SupportEyePoint Pharmaceuticals has a significant cash reserve of $415 million, which supports its development and operational activities effectively.
Logistics And Market PositionDuravyu is administered intravitreally and can be shipped and stored at room temperature, simplifying supply logistics and enhancing its market positioning.
Product Efficacy And Market PotentialDuravyu has shown remarkable rapid visual and structural improvements in diabetic macular edema, indicating a positive treatment outcome.
Bears Say
Clinical TrialsRisks include the possibility of EYP-1901 failing in clinical trials or not obtaining regulatory approval.
Competitive ChallengesThe path forward for CLS-AX is seen as potentially challenging both clinically and commercially, reinforcing the competitive edge for EYPT.
ValuationPotential dilution risk is a concern for the valuation of the company.
---
Ownership Overview
13.16% Insiders
19.18% Mutual Funds
0.23% Other Institutional Investors
57.46% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EYPT FAQ
What was Eyepoint Pharma’s price range in the past 12 months?
Eyepoint Pharma lowest stock price was $6.90 and its highest was $30.99 in the past 12 months.
What is Eyepoint Pharma’s market cap?
Eyepoint Pharma’s market cap is $496.18M.
When is Eyepoint Pharma’s upcoming earnings report date?
Eyepoint Pharma’s upcoming earnings report date is Feb 27, 2025 which is in 36 days.
How were Eyepoint Pharma’s earnings last quarter?
Eyepoint Pharma released its earnings results on Nov 07, 2024. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.546 by $0.006.
Is Eyepoint Pharma overvalued?
According to Wall Street analysts Eyepoint Pharma’s price is currently Undervalued.
Does Eyepoint Pharma pay dividends?
Eyepoint Pharma does not currently pay dividends.
What is Eyepoint Pharma’s EPS estimate?
Eyepoint Pharma’s EPS estimate is -0.49.
How many shares outstanding does Eyepoint Pharma have?
Eyepoint Pharma has 68,251,030 shares outstanding.
What happened to Eyepoint Pharma’s price movement after its last earnings report?
Eyepoint Pharma reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.546. Following the earnings report the stock price went down -4.056%.
Which hedge fund is a major shareholder of Eyepoint Pharma?
Currently, no hedge funds are holding shares in EYPT
---
EyePoint Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.43 (293.45% Upside)
$29.43 (293.45% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 321.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.79%
12-Months-Change
Fundamentals
Return on Equity
-74.68%
Trailing 12-Months
Asset Growth
88.02%
Trailing 12-Months
Company Description
Eyepoint Pharma
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
---
EYPT Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in financial strength, strategic transformation, and positive clinical trial results. The main challenge noted was a decrease in net product revenue due to exiting the commercial business, but this was part of a strategic shift. Overall, the sentiment is positive as the company is well-capitalized and on track with its clinical and strategic goals.Read More>---
EYPT Stock 12 Month Forecast
Average Price Target
$29.43
▲(293.45% Upside)
Technical Analysis
Outlook Therapeutics
―
Ocular Therapeutix
―
Kala Pharmaceuticals
―
Aldeyra Therapeutics
―
Curis
―
Best Analysts Covering EYPT
1 Year
1 Year Success Rate
9/23 ratings generated profit
1 Year Average Return
+51.61%
reiterated a buy rating 2 months ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 39.13% of your transactions generating a profit, with an average return of +51.61% per trade.
---